Use of des-Aspartate-angiotensin I as an agent for the treatment

Details Use of des-Aspartate-angiotensin I as an agent for the treatment Use of des-Aspartate-angiotensin I as an agent for the treatment

1998-10-14

2000-08-08

Criares, Theodore J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

A61K 3800

Patent

active

061002372

ABSTRACT:
The use of des-Aspartate-angiotensin I (Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) as an anti-neointima and anti-arteriosclerotic agent was described. The compound, given intravenously attenuates the development of neointima formation in balloon catheter-injured carotid arteries of Sprague Dawley rats. The anti-neointima action was dose-dependent and the maximum effect was obtained with a dose of 10 pmoles/day given 2 days pre- and 13 days post-balloon catheterization. When given orally on a chronic basis at a dose of 0.9 mg/kg/day for 47 weeks, the compound significantly attenuates the development of arteriosclerosis in the spontaneously hypertensive rats. The anti-arteriosclerotic action was not blood pressure dependent.

REFERENCES:
patent: 5773415 (1998-06-01), Sim

Affiliated with

Also associated with

Rating

Use of des-Aspartate-angiotensin I as an agent for the treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of des-Aspartate-angiotensin I as an agent for the treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of des-Aspartate-angiotensin I as an agent for the treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1150221